Clinical Trial ResultsA Nstat monotherapy cohort, required by the FDA, showed limited efficacy with only a 10% overall response rate in treated patients.
Drug Efficacy And Market CompetitionRisks include potential inability to generate further favorable clinical data, failure to secure accelerated FDA approval, and possible poorer market uptake due to competition or other factors.
Drug Safety ConcernsInvestor concerns arose due to a serious adverse event related to the drug that resulted in a patient's death from pancytopenia and sepsis.